TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Recall of pictures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Expression levels of serum exosome long non-coding RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of tumor biomarkers (CEA, NSE, SCC, CYFR2A-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CT scans of the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concentration of caplacizumab in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arginase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short-Musculoskeletal Function Assessment - Dysfunction Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in lipid levels (LDL-C, HDL-C, TG, TC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of candidaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antifungal susceptibility patterns of Candida spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Worker Productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Elliptical Device Pedaling Quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Centration of Optimal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient truthfulness - biometric mouse-movement distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient truthfulness - biometric mouse-movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient truthfulness Weight - answer adjustment from -5 to 5 for each health question
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inventory of Psychosocial Functioning (IPF) - Romantic, Family, Friends/Socializing Subscales
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Veterans Rand 12-item (VR-12) Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Symptom Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of development of new active lesions on MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase of at least one weekly complete spontaneous bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase of at least two weekly complete spontaneous bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success of ECV procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of CTED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of topical application of norepinephrine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with grade 3 through grade 5 new neurological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue mechanical properties of the liver and liver tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteremia incidence after trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduce bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade 3 allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Grade 4 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Grade 4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Grade 3 or 4 organ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of imatinib mesylate
Endpoint domain: Adverse events/effects
Primary endpoint: Modified COVID Ordinal Outcomes Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gestational diabetes mellitus (DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of hospitalizations due to exacerbation of COPD avoided
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change From Baseline in Menopause Rating Scale Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Comfort and safety evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of specific biomarker(s) for brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of early dementia
Endpoint domain: Mortality/survival
Primary endpoint: Initial success rate of temporary FCMS placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blister/Erosion Reduction Based on Change in Body Surface Area (BSA) Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Target Wound Size Reduction or Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Physician Global Assessment of Severity (PGAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in 24-hour systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thrombin generation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of asymptomatic children or children with mild respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma vasopressin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient response to therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response (CR + PR) of Melanoma Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: freedom from a major adverse event (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: improved swallowing function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of repigmentation on target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of visual assessment of stenosis significance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of pain level by 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the use of back-up medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Average Daily Pain Intensity Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Withdrawals Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the number of individuals requiring pharmacotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: State-trait anxiety inventory (STAI-Y) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recruitment-to Inflation ratio (R/I ratio)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Implementation of prediction models
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment safety
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Exercise Pulmonary Capillary Wedge Pressure (PCWP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Saphenous vein graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diversity of antigen-receptors' repertoires
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Outcome Compliance Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment Compliance Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in serum concentration of creatine kinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum concentration of highly sensitive C-reactive protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Contrast Induced-Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intracuff Pressure During Probe Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracuff Pressure With Probe in Place
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracuff Pressure After Probe Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic stiffness evaluated by pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fat measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fitting of the garment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Took Appropriate Action Based on Their LDL-C Results
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of VTE Events
Endpoint domain: Adverse events/effects
Primary endpoint: Self Care Behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sustained platelet count response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of UI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Time in Target Range of 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain as measured by McGill Short Form Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain as measured by Nurse Graphic Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and anxiety as measured by Graphic Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Glutamic Oxaloacetic Transaminase (AST/SGOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Serum Glutamic Pyruvate Transaminase (ALT/SGPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Total Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with at least one treatment emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma concentration (Cmax) of Debio 1450
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum observed plasma concentration (tmax) of Debio 1450
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of the amplitude of sleep slow oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: 4-hour triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in metabolic syndrome incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weekly Average of Daily Worst Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to diagnosis of recurrent BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined Counts of Adverse Events of Flu-Like Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Combined Counts of Adverse Events of Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Combined Counts of Adverse Events of Injection Site Reaction Pain
Endpoint domain: Adverse events/effects
Primary endpoint: Gross Motor Function Measure Dimension E
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Activity Measured by StepWatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Measure Dimension D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: advanced glycation end-product (AGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: inflammatory cytokines (TNF-alfa, IL-6 and MCP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cardiac function (echo and BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of Provider Assessment of Asthma Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Clinician Assessment of Patient Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of appropriateness of asthma treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with provider-patient communication and medical care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Area Under the Curve 0-8h (AUC0-8h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with local or systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in symptoms assessment score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of Any Major Thromboembolic Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Free disease time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients with 50% or Greater Wound Size Volume Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surprise question
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: detection of subclinical atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in diffusion-weighted MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants completing the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: complete histological response rate (absence of tumor cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) of Insulin Lispro
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of Insulin Lispro Glucose Following a Mixed Meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endogenous fibrinolysis (net release of plasma t-PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: drug level of fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAR-T Cell expansion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG depression and arousal reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of intestinal metaplasia, intraepithelial neoplasia, and gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Readmission Rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Fraction of inspired oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional and/or structural changes in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in perception of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual Gastric Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Initiation of contraception
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: AG120 Area Under the Curve [AUC]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AG120 Maximum Plasma Concentration [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itraconazole Area Under the Curve [AUC]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itraconazole Maximum Plasma Concentration [CMAX]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastric insufflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distancing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retinal Thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in UPDRS Part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in NITFBUT at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With GD Diagnosis Confirmed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Contraceptive Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placement Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Death by 14 days
Endpoint domain: Mortality/survival
Primary endpoint: gingival recession width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients in Remission at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum area-under-the-curve (AUC) of PF708 and Forteo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum maximum concentration (Cmax) of PF708 and Forteo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of periprosthetic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion of Barrett's esophagus to adenocarcinoma or high-grade dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With NASH Resolution Without Worsening of Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anti-A antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-B antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of immunoparalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of immunoparalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC and CMAX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Prosthetic joint infection
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in respiratory quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes